Also known as: LY-3437943
Triple GLP-1R/GIPR/GcgR agonist studied for weight loss, showing the largest reductions in Phase II trials to date.
📖 Read the full Retatrutide research overview →
Evidence Tier: Tier 2 — Clinical Trials · Peptidings Verdict: Reasonable Bet